Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Sergio A. Giralt"'
Autor:
Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura, Sean M. Devlin, Tasmin Farzana, Sridevi Rajeeve, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Alexander M. Lesokhin, Urvi A. Shah, Carlyn R. Tan, Sergio A. Giralt, Saad Z. Usmani, Karthik Nath, Sham Mailankody
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on chi
Externí odkaz:
https://doaj.org/article/b0599253316a411c8f7c1eb08d801e0c
Autor:
Karthik Nath, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Bruno Almeida Costa, Noriko Nishimura, Tasmin Farzana, Colin Rueda, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Neha Korde, Urvi A. Shah, Carlyn Rose Tan, Malin Hultcrantz, Sergio A. Giralt, Saad Z. Usmani, Zainab Shahid, Sham Mailankody, Alexander M. Lesokhin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targ
Externí odkaz:
https://doaj.org/article/6b93aedeb2774601928a329b4bbfda19
Autor:
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Sydney X Lu, Dhwani Patel, Urvi Shah, Carlyn Tan, Andriy Derkach, Oscar Lahoud, Heather J Landau, Gunjan L. Shah, Michael Scordo, David J Chung, Sergio A Giralt, Saad Z Usmani, Ola Landgren, Malin Hultcrantz
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/b09112b44eb5465496879b234943ba11
Autor:
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression
Externí odkaz:
https://doaj.org/article/cffbd554fa414cab9e44d309fb48abab
Autor:
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 6, Pp 1-11 (2022)
Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eve
Externí odkaz:
https://doaj.org/article/0238267280cc4458be0fc24b8b97fe2d
Autor:
Maria A. Malik, Nathan W. Sweeney, Mohammad Jafri, Andriy Derkach, Cynthia Chmielewski, Peter A. Adintori, Sham Mailankody, Neha Korde, Carlyn R. Tan, Hani Hassoun, Malin Hultcrantz, Jens Hillengass, Susan E. McCann, Neil Iyengar, Saad Usmani, Sergio A. Giralt, Ola Landgren, Marcel R. M. van den Brink, Jennifer M. Ahlstrom, Alexander M. Lesokhin, Anita D’Souza, Susan Chimonas, Urvi A. Shah
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-5 (2022)
Externí odkaz:
https://doaj.org/article/68536ec941d147189e0677f18c00e7f0
Autor:
Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S. Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-8 (2020)
Abstract Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapse
Externí odkaz:
https://doaj.org/article/389f883efb66456f8cfaa6345ac27639
Autor:
Ioannis Politikos, Jessica A. Lavery, Patrick Hilden, Christina Cho, Taylor Borrill, Molly A. Maloy, Sergio A. Giralt, Marcel R.M. van den Brink, Miguel-Angel Perales, Juliet N. Barker
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 191-202 (2020)
Abstract: Quality of immune reconstitution after cord blood transplantation (CBT) without antithymocyte globulin (ATG) in adults is not established. We analyzed immune recovery in 106 engrafted adult CBT recipients (median age 50 years [range 22-70])
Externí odkaz:
https://doaj.org/article/7cf6f89275e844b2a0f320e02d965d85
Autor:
Michael Scordo, Leah J. Gilbert, Danielle M. Hanley, Jessica R. Flynn, Sean M. Devlin, Linh K. Nguyen, Josel D. Ruiz, Gunjan L. Shah, Craig S. Sauter, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Richard J. Lin, Parastoo B. Dahi, Miguel-Angel Perales, Sergio A. Giralt, Gerald A. Soff
Publikováno v:
Blood Advances. 7:1536-1544
There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen–induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT). We conducted an open-label, single-arm pilot stud
Autor:
Theresa A. Elko, MPAS, PA-C, Samantha Brown, MS, Stephanie Lobaugh, MS, Sean Devlin, PhD, Ann A. Jakubowski, MD, PhD, Miguel-Angel Perales, MD, Molly A. Maloy, MS, Allison J. Applebaum, PhD, Sergio A. Giralt, MD, Lauren Levy, MS, PA-C, Anne Schneider, LMSW, Richard J. Lin, MD, PhD
Publikováno v:
Journal of the Advanced Practitioner in Oncology. 14:127-137
Older patients with hematologic malignancies are increasingly considered for allogeneic hematopoietic cell transplant (allo-HCT). However, older patients often have increased comorbidities and thus may require an increased level of post-transplant ca